May 16, 2016 / 1:02 PM / a year ago

BRIEF-Theratechnologies and partner evaluating steps to seek and obtain approval of 1 mg/vial presentation

May 16 (Reuters) - Theratechnologies Inc

* Decided to withdraw marketing authorization application for registration of 2 mg/vial presentation of tesamorelin in Brazil

* Co and its partner are currently evaluating required steps to seek and obtain approval of 1 mg/vial presentation

* Decision by co, Sanofi based on receipt of questions asked by regulatory authority, ANVISA

* Decision by co, Sanofi also based on , fact that presentation is no longer available in any other territory Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below